Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay
Fine Closes ‘Pay-For-Delay’ Investigation That Began In 2011
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.
You may also be interested in...
A European Commission investigation into Teva’s conduct over its Copaxone multiple sclerosis drug has led to the firm receiving a statement of objections, which details a preliminary finding that the company violated EU antitrust laws.
Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.
$1.2 billion agreement resolving Provigil litigation with FTC blocks Teva from entering business deal with competitor until 30 days after patent settlement that restricts generic entry, sets $7 million cap on litigation savings.